Literature DB >> 11740743

High intralesional interleukin-10 messenger RNA expression in localized cutaneous leishmaniasis is associated with unresponsiveness to treatment.

E Bourreau1, G Prévot, J Gardon, R Pradinaud, P Launois.   

Abstract

The intralesional expression of cytokines (interleukin [IL]-4, IL-13, IL-10, and interferon-gamma) was analyzed in 65 patients with localized cutaneous leishmaniasis due to Leishmania guyanensis before specific treatment with pentamidine isethionate. The local expression of IL-10 was significantly higher in patients who responded poorly to treatment than in patients whose lesions were regressing. When an IL-10 level >10 (ratio of the concentration of IL-10 [pg/microL] to that of beta-actin [pg/microL]) was used as an indicator of treatment failure, the sensitivity of this test was 78.6, and the specificity was 72.5. Thus, high intralesional expression of IL-10 might predict a poor response to conventional treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11740743     DOI: 10.1086/324665

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  26 in total

Review 1.  Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

Authors:  Anke E Kip; Manica Balasegaram; Jos H Beijnen; Jan H M Schellens; Peter J de Vries; Thomas P C Dorlo
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  Regulatory T-Cell Dynamics in Cutaneous and Mucocutaneous Leishmaniasis due to Leishmania braziliensis.

Authors:  Nicolas Barros; Nestor Vasquez; Fernando Woll; Cesar Sanchez; Braulio Valencia; Alejandro Llanos-Cuentas; A Clinton White; Martin Montes
Journal:  Am J Trop Med Hyg       Date:  2018-02-01       Impact factor: 2.345

Review 3.  Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies.

Authors:  Ifeoma Okwor; Jude Uzonna
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

4.  In situ immunopathological changes in cutaneous leishmaniasis due to Leishmania donovani.

Authors:  N H Manamperi; S Oghumu; N Pathirana; M V C de Silva; W Abeyewickreme; A R Satoskar; N D Karunaweera
Journal:  Parasite Immunol       Date:  2017-03       Impact factor: 2.280

5.  Immunological determinants of clinical outcome in Peruvian patients with tegumentary leishmaniasis treated with pentavalent antimonials.

Authors:  Anne Maurer-Cecchini; Saskia Decuypere; François Chappuis; Coralie Alexandrenne; Simonne De Doncker; Marleen Boelaert; Jean-Claude Dujardin; Louis Loutan; Jean-Michel Dayer; Gianfranco Tulliano; Jorge Arevalo; Alexandro Llanos-Cuentas; Carlo Chizzolini
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

6.  Sand fly saliva enhances Leishmania amazonensis infection by modulating interleukin-10 production.

Authors:  Nilufer B Norsworthy; Jiaren Sun; Dia Elnaiem; Gregory Lanzaro; Lynn Soong
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

7.  Immunological perspectives of leishmaniasis.

Authors:  Susanne Nylén; Shalini Gautam
Journal:  J Glob Infect Dis       Date:  2010-05

8.  Inbred strains derived from feral mice reveal new pathogenic mechanisms of experimental leishmaniasis due to Leishmania major.

Authors:  Besma E C Babay; Hechmi Louzir; Chahnaz Kebaïer; Samir Boubaker; Koussay Dellagi; Pierre-André Cazenave
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

9.  Impaired expression of inflammatory cytokines and chemokines at early stages of infection with Leishmania amazonensis.

Authors:  Jiaxiang Ji; Jiaren Sun; Lynn Soong
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

10.  Can interferon-gamma and interleukin-10 balance be associated with severity of human Leishmania (Viannia) braziliensis infection?

Authors:  A Gomes-Silva; R de Cássia Bittar; R Dos Santos Nogueira; V S Amato; M da Silva Mattos; M P Oliveira-Neto; S G Coutinho; A M Da-Cruz
Journal:  Clin Exp Immunol       Date:  2007-07-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.